NR2F6

Across TCGA pan-cancer cohorts, NR2F6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NR2F6 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NR2F6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NR2F6 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, UCEC, and BLCA are the cancer types where NR2F6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	II,III,IV	1.000	0.329	.048	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NR2F6–STAD (OS)

Open the STAD breakdown →